Author

Trishala Agrawal

Institution: Johnson & Johnson (United States)

Observed institutions: Tongji University, Newark Beth Israel Medical Center, Johnson & Johnson (United States), Yonsei University, University of Ulsan, Arog Pharmaceuticals (United States), Shanghai Pulmonary Hospital, The First Affiliated Hospital, Sun Yat-sen University, Yonsei Cancer Hospital, Janssen Research & Development (United States), Sungkyunkwan University

OpenAlex ID: A5032586715

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

2023 · Caicun Zhou, Ke-Jing Tang, et al. · New England Journal of Medicine · 391

Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant

2018 · Betul Oran, Stefan O. Ciurea, et al. · Blood · 6

Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated EGFR -mutated non-small-cell lung cancer

2024 · Joshua K Sabari, Nicolas Girard, et al. · Future Oncology · 3

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

2026 · Caicun Zhou, Ke-Jing Tang, et al. · Lung Cancer · 2

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study

2025 · Rachel E. Sanborn, Caicun Zhou, et al. · Targeted Oncology · 2

Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis.

2024 · Ke-Jing Tang, Baogang Liu, et al. · Journal of Clinical Oncology · 2

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

2025 · Luis Paz-Ares, Remi Veillon, et al. · Lung Cancer · 1

Patient-reported outcomes in non-small cell lung cancer: psychometric evaluation of the PROMIS PF-SF 8c and NSCLC-SAQ in two phase 3 clinical trials

2024 · Carrie R. Houts, Andrea Savord, et al. · Quality of Life Research · 1

Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial

2026 · Kejing Tang, Fengying Wu, et al. · Chinese Medical Journal

Development of the Weight‐Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin‐Pemetrexed in EGFR ‐Mutated Non‐Small Cell Lung Cancer

2026 · Dongfen Yuan, Corey J. Bishop, et al. · CPT Pharmacometrics & Systems Pharmacology

Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC

2025 · Satoru Kitazono, Akira Ono, et al. · Cancer Science

Patient-Reported Outcomes and Time to Symptomatic Progression from Papillon: Amivantamab Plus Chemotherapy vs Chemotherapy as First-Line Treatment of Egfr Exon 20 Insertion-Mutated Advanced Nsclc

2025 · Luis Paz Ares, Remi Veillon, et al. · SSRN Electronic Journal

Population Pharmacokinetics and Exposure-Response Relationship of Amivantamab in Combination with Carboplatin-Pemetrexed: Analyses from PAPILLON Supporting the Weight-Tiered Q3W Regimen

2024 · Dongfen Yuan, Wangda Zhou, et al.

Clinical and Economic Impact of Pre-Operative Coagulation Screening in Children

2012 · Trishala Agrawal, Louisa Mazza-Hilway, et al. · Blood

Overuse of Cryoprecipitate: A Chronic Condition,

2011 · Manpreet K. Sandhu, Trishala Agrawal, et al. · Blood

Works count: 15

Citation count: 406

H-index: 3

I10-index: 1